GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.22
+0.29 (+0.73%)
At close: 4:02PM EDT

40.23 +0.01 (0.02%)
After hours: 5:25PM EDT

Stock chart is not supported by your current browser
Previous Close39.93
Open40.03
Bid40.21 x 2200
Ask40.22 x 1800
Day's Range39.89 - 40.24
52 Week Range36.41 - 42.36
Volume2,029,093
Avg. Volume2,650,983
Market Cap99.158B
Beta (3Y Monthly)0.54
PE Ratio (TTM)40.54
EPS (TTM)0.99
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.39 (5.71%)
Ex-Dividend Date2019-02-21
1y Target Est44.33
Trade prices are not sourced from all markets
  • Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?
    Zacks10 hours ago

    Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?

    Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.

  • Pfizer Stock Has Positive and Negative Catalysts Going Into Results
    InvestorPlace12 hours ago

    Pfizer Stock Has Positive and Negative Catalysts Going Into Results

    Pfizer (NYSE:PFE) stock has missed out on the exuberant bull market this year, as the indexes have hit all-time highs, but Pfizer stock has fallen about 10% in 2019.Source: Shutterstock Then again, the company's growth has been lagging, and PFE has felt pressure from Washington, DC to reduce its drug prices.But next week we'll get more information on the status of the company, as it will report its first-quarter results. They will be announced on Apr. 30 before the market opens.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Dividend Stocks That Could Double Over the Next Five Years Analysts' expectations for Pfizer stock are fairly muted. For the quarter, on average they predict that its revenues will be $13 billion and its earnings will be 75 cents per share of Pfizer stock By comparison, in the same period a year ago, its revenues were $12.9 billion and its earnings were 77 cents per share.It's important to keep in mind that, when PFE last reported its financial results, it provided full-year revenue guidance of $52 billion to $54 billion. Last year, its top line came in at $53.6 billion.The big issue for Pfizer stock has been its pain killer, Lyrica. This drug, which generated close to $5 billion of revenue last year, will lose its patent protection in June. Moreover, the sales of a number of PFE's other drugs have slowed this year.But PFE's pipeline does look promising, creating potential positive catalysts for PFE stock. Last quarter, the company announced several positive catalysts involving its pipeline. Specifically: * Pfizer and Bristol-Myers Squibb (NYSE:BMY) have been developing a new version of Eliquis, which has been shown to effectively treat the bleeding of heart attack patients. A recent study of Eliquis indicated that its efficacy in this area was significantly better than that of a warfarin combination. * The FDA granted a Breakthrough Therapy Designation for Pfizer's 20-Valent Pneumococcal Conjugate Vaccine (20vPnC). The treatment is supposed to prevent people from getting pneumonia, and it appears to be much more effective than the vaccines that are currently on the market. * The European Commission approved VIZIMPRO, which is a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC). * In Q1, Pfizer continued its big push into the gene-therapy market. The company announced that it had created a partnership with Vivet Therapeutics. The companies will focus on developing a treatment for Wilson disease , a rare condition that leads to copper poisoning. * The FDA approved Pfizer's TRAZIMERA, a treatment for breast cancer.Going forward, a number of Pfizer's major drugs, including Xeljanz and Ibrance., should be approved as treatments for additional diseases. Furthermore, the sales of several other Pfizer treatments -including atopic dermatitis treatments tafamidis and abrocitinib, as well as pain medication tanezumab - could surge tremendously. The Bottom Line on Pfizer StockPfizer stock is trading at reasonable levels, as its forward price-earnings ratio is below 13. That's in-line with the valuations of other mega pharma operators like Merck (NYSE:MRK) and GlaxoSmithKline (NYSE:GSK).Pfizer also has a long history of being shareholder-friendly. The dividend yield of PFE stock is 3.4% and the company continues to buyback large amounts of Pfizer stock. PFE bought back $12.2 billion of PFE stock last year.However, there probably will not be any near-term catalysts for PFE stock. The political pressure will remain an overhang on Pfizer stock, especially as we get closer to the presidential election. Meanwhile, it will take some time for the company's pipeline to boost its revenue and profits. As a result, investors shouldn't rush to buy Pfizer stock.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Double Over the Next Five Years * 6 S&P 500 Stocks Ready to Break Out * 5 Mining ETFs to Dig Into Compare Brokers The post Pfizer Stock Has Positive and Negative Catalysts Going Into Results appeared first on InvestorPlace.

  • Exelixis (EXEL) to Report Q1 Earnings: What's in Store?
    Zacks12 hours ago

    Exelixis (EXEL) to Report Q1 Earnings: What's in Store?

    Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.

  • Top 5 Dividend Stocks in the FTSE for 2018
    Investopediayesterday

    Top 5 Dividend Stocks in the FTSE for 2018

    The FTSE 100 is an index that includes the top 100 companies from the London Stock Exchange. They are ranked by their market capitalization. However, market cap may not be an investor’s only interest in a stock.

  • Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
    Zacksyesterday

    Lannett (LCI) to Report Q3 Earnings: What's in the Cards?

    Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches

  • Associated Pressyesterday

    Drug maker to spend $100M expanding Montana facility

    HAMILTON, Mont. (AP) — Drugmaker GlaxoSmithKline has announced $100 million of new investment in its manufacturing site in Montana.

  • Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
    Zacksyesterday

    Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y

    Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.

  • Financial Times2 days ago

    Malawi starts pilot of malaria vaccine for children

    A large-scale pilot of a vaccine that could prevent some of the 250,000 child deaths each year from malaria has begun in Malawi after successful clinical trials. The vaccine — called RTS,S — acts against the most deadly malaria parasite and has been in development by GlaxoSmithKline for more than three decades. According to the World Health Organization, it is the first vaccine to demonstrate it can significantly reduce cases of malaria in children.

  • Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
    Zacks2 days ago

    Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?

    Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.

  • What's in Store for Celgene Corporation (CELG) Q1 Earnings?
    Zacks2 days ago

    What's in Store for Celgene Corporation (CELG) Q1 Earnings?

    Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.

  • Are Investors Undervaluing GlaxoSmithKline (GSK) Right Now?
    Zacks3 days ago

    Are Investors Undervaluing GlaxoSmithKline (GSK) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • 2 Best Biotech Buyout Plays
    Motley Fool3 days ago

    2 Best Biotech Buyout Plays

    Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.

  • What's in Store for Bayer (BAYRY) This Earnings Season?
    Zacks3 days ago

    What's in Store for Bayer (BAYRY) This Earnings Season?

    Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.

  • Will Bristol-Myers (BMY) Disappoint This Earnings Season?
    Zacks4 days ago

    Will Bristol-Myers (BMY) Disappoint This Earnings Season?

    Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.

  • GSK cutting employees at its R&D unit in Collegeville
    American City Business Journals6 days ago

    GSK cutting employees at its R&D unit in Collegeville

    The changes are part of a new approach to R&D; prioritizing innovation and moving towards delivering a pipeline of medicines with a focus on immunology.

  • Clovis Focuses on Rubraca Label Expansion, Competition Stiff
    Zacks7 days ago

    Clovis Focuses on Rubraca Label Expansion, Competition Stiff

    Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.

  • COPD space about to have another drug — this time from a Morrisville concern
    American City Business Journals8 days ago

    COPD space about to have another drug — this time from a Morrisville concern

    A recent FDA approval has one Triangle pharmaceutical company going head to head with the likes Pharma giants such as GSK – in an multi-billion dollar industry company officials believe they have the edge in.

  • Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
    Zacks8 days ago

    Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

    Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

  • Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
    Zacks9 days ago

    Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up

    Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.

  • Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
    Zacks9 days ago

    Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

    The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.

  • Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
    Zacks10 days ago

    Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

    Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.

  • Reuters11 days ago

    London's FTSE 100 tugged down by miners; IWG lifts midcaps

    (Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...

  • Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
    Zacks13 days ago

    Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group

    Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.

  • Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
    Zacks13 days ago

    Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

    Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

  • Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
    Zacks14 days ago

    Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon

    Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.